Cargando…
A Rare Case of Large-Vessel Vasculitis following Checkpoint Inhibitor Therapy and Pegfilgrastim
Checkpoint inhibitors (CPIs) and pegfilgrastim, a long-acting growth factor agent, are vital components of current cancer treatments. Immune-related adverse events (irAEs) such as colitis and pneumonitis are well-established toxicities associated with CPI therapy. However, large-vessel vasculitis se...
Autores principales: | Mort, Joseph, Maheshwari, Shipra, Basu, Nayanika, Dillon, Patrick, Brady, Kevin, Bear, Harry, Millard, Trish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890883/ https://www.ncbi.nlm.nih.gov/pubmed/35251725 http://dx.doi.org/10.1155/2022/7295305 |
Ejemplares similares
-
COVID-19-Vaccine-Pfizer-BioNTech/pegfilgrastim/pembrolizumab: Large vessel vasculitis: case report
Publicado: (2022) -
Checkpoint inhibitor–associated cutaneous small vessel vasculitis
por: Castillo, Brianna, et al.
Publicado: (2018) -
Small vessel vasculitis
por: Brogan, Paul, et al.
Publicado: (2009) -
Large vessel vasculitis
por: Gulati, Ashima, et al.
Publicado: (2009) -
Medium-size-vessel vasculitis
por: Dillon, Michael J., et al.
Publicado: (2009)